Objective: To observe the clinical efficacy of heat-sensitive moxibustion plus medications on senile osteoporosis (SOP), and to explore the related mechanisms. Methods: A total of 70 elderly participants with osteoporosis were randomly divided into an observation group and control group, with 35 cases in each group. The control group was treated with conventional drugs, and the observation group was treated with heat-sensitive moxibustion on the basis of the conventional drugs. Both groups were treated for 3 months. Before and after treatment, assessed the visual analog scale (VAS) and Oswestry disability index (ODI) scores, determined the bone mineral density of the participants' lumbar spine (L2-L4) and left femoral neck, and detected the participants' serum bone morphogenetic protein-2 (BMP-2) and osteoprotegerin (OPG) levels. Results: After treatment, the VAS scores of both groups were lower than before treatment (both P<0.05), and the VAS score of the observation group was significantly lower than that of the control group (P<0.05). After treatment, the bone mineral density values of the lumbar spine and left femoral neck in both groups were significantly higher than before treatment (both P<0.05), and the bone mineral density values of the observation group were higher than those of the control group (P<0.05). After treatment, the ODI scores of the two groups were lower than those before treatment (both P<0.05), and the ODI score of the observation group was lower than that of the control group (P<0.05). After treatment, the serum BMP-2 and OPG levels in the observation group were significantly higher than those in the control group (both P<0.05). Conclusion: Heat-sensitive moxibustion plus medications for SOP can significantly relieve patients' pain, improve dysfunction, and increase bone density, which may be related to the improvement of the serum BMP-2 and OPG levels.

With the concept of vascular cognitive impairment has been deeply recognized and the thorough studies of its pathogenesis,study reports on vascular cognitive impairment have been increasing in recent years.This article reviews the molecular mechanism and genetics of vascular cognitive impairment.

Objective To evaluate the long-term clinical efficacy and security of levetiracetam (Lev) as add-on therapy in patients with different types of epilepsies from an observational study.Methods Fifty-one patients were evaluated (14 female,37male,age range from 7months to 16 years,mean age 8.7 years) with different types of epilepsies ( 20 complex partial seizure,10 tonic-clonic seizure,1 tonic seizure,6 myoclonic epilepsy,2 Lennox-Gastaut syndrome,4 infantile spasms and 2 unspecified epileptic syndromes).The basis for comparison was defined as the seizure frequency in the 3 months prior to the commencement of treatment.Patients received Lev as add-on therapy.The initial dosage was 20 mg/(kg?d),and it was increased 10 mg/(kg?d) every 2 weeks.The maintenance dosage was 30-40 mg/(kg?d).Seizure frequency changes and adverse events were observed.Follow-up was conducted for a period of 6.8 months after treatment.SPSS 14.0 software was used to compare the difference between the seizure frequency before the Lev treatment and that after the Lev treatment.Results Thirteen (25.5%) out of the 51 patients reduced seizure frequency,16 (31.4%) patients had no reoccurrence;While another 9 (17.6%) patients seizure frequencied were reduced,8 patients' remained the same,and 5 patients' condition was got wor-sened.Six cases ceased treatment because of the worsening of the disease and the intolerance of Lev.The difference and after seizure frequency before in Lev treatment is statistically significant(P

0.05).The period when epileptiform abnormalities appear was obviously different(P

0.05).Of essay group 19 children whose PET were normal or slight abnormal,8 children's VEEG had epileptifrom abnormalities only appear in lucid interval,8 children's VEEG had epileptifrom abnormalities appear in nocturnal sleep period,3 children's VEEG had epileptifrom abnormalities appear in lucid interval and nocturnal sleep period.Of essay group,7 children whose PET were serious abnormal,6 children's VEEG had epileptifrom abnormalities appear in lucid interval and nocturnal sleep period.The PET outcome was relate with the time of VEEG epileptic discharge(r=0.461 P

Aged ; Castleman Disease ; complications ; Hepatitis B ; complications ; Humans ; Liver Neoplasms ; complications ; virology ; Lymphoma, Non-Hodgkin ; complications ; Male

Acupuncture Points ; Acupuncture Therapy ; Adult ; Combined Modality Therapy ; Exercise Therapy ; Female ; Humans ; Male ; Middle Aged ; Tennis Elbow ; therapy ; Young Adult

Child ; Embolization, Therapeutic ; adverse effects ; methods ; Female ; Humans ; Male ; Platelet Count ; Purpura, Thrombocytopenic, Idiopathic ; blood ; therapy ; Splenic Artery

Objective: To investigate the reversal effect of astragaloside IV on multidrug resistance of MDA-MB-231/DOX in breast cancer cells. Methods: The cytotoxicity of astragaloside IV and sensitivity or drug resistance of breast cancer cells to doxorubicin (DOX) before and after treatment were determined by MTT assay. Liposome co-delivery system containing doxorubicin and astragaloside IV (LPs-DOX/AS) was constructed by ethanol injection-ammonium sulfate gradient method. The reversal effect of LPs-DOX/AS on multidrug resistance of breast cancer cells was determined by MTT method. The effect of LPs-DOX/AS on apoptosis was determined by flow cytometry. Results: Astragaloside IV had no significant cytotoxicity to breast cancer cells in the experimental concentration range. After combined with astragaloside IV, the IC50 values of DOX on MDA-MB-231 and MDA-MB-231/DOX cells decreased (P < 0.05), and the intervention effect on drug-resistant cells was more significant (P < 0.01). Compared with free DOX/AS-IV, the IC50 values of LPs-DOX/AS-IV on both breast cancer cells decreased (P < 0.05), and the effect on drug-resistant strains was more significant (P < 0.01). The apoptosis rate of drug-resistant strains treated with LPs-DOX/AS-IV was also significantly higher than that of free drug group (P < 0.05). Conclusion: Astragaloside IV has reversal effect on multidrug resistance of human breast cancer cell MDA-MB-231 to doxorubicin. The combination of astragaloside IV and doxorubicin and its liposome co-delivery system can effectively reverse or sensitize multidrug resistance in breast cancer.

The enzymatic degumming of ramie bast fibers is a kind of method with high performance, superior quality, free from pollution that directly makes use of the extra cellular enzyme or zymin produced in the fermentation process of microorganisms to degrade the gum. So far, many investigations regarding this aspect have been conducted at home and abroad, and screened various strains including aerobic bacteria and anaerobic bacteria. Comparison with the chemical degumming, the enzymatic degumming shows the advantage of improving the quality of refined dried-ramie, significantly lowering the pollution of the environment, and isone of the main development directions in the future. At the same time, if the degumming technology is extensively applied into industrialization production, the dosage of enzymes will prodigiously increase, which will promote the development of the industry on enzymes.